Search - tctmd.com

Displaying 1 - 20 of 176

Sort: Relevancy | Date

DES Best for In-Stent Restenosis, but DCBs Also Viable

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

DCB in STEMI Match DES Through 5 Years: REVELATION

News Daily News

DCB in STEMI Match DES Through 5 Years: REVELATION

March 27, 2024

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

News Conference News TCT 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

Michael O'Riordan

October 15, 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

October 22, 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

October 17, 2020

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

News Daily News

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

October 09, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

September 24, 2020

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

March 09, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

January 15, 2020

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

STEMI Care and Outcomes Still Affected by Socioeconomic Status, Insurance

News Daily News

STEMI Care and Outcomes Still Affected by Socioeconomic Status, Insurance

Yael L. Maxwell

January 09, 2019

Top News in Coronary Artery Disease: 2018

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

September 22, 2018

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

News Conference News ESC 2018

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

August 28, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.